Michael James  Newman net worth and biography

Michael Newman Biography and Net Worth

A founder of the company, Dr. Michael Newman currently serves as our Chief Scientific Officer. Most recently, he was Founder and CEO of Decoy Biosystems, where he developed the technology that serves as the foundation of Indaptus. With more than 35 years of experience carrying out and managing oncology drug discovery through early development in academia and at pharmaceutical and biotechnology companies, Michael has also served as a consultant to ~35 companies, assisting with target identification and prioritization, management of R&D, fundraising, and in/out-licensing. His previous positions include faculty appointments in biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), Executive Director of Oncology at Novartis Pharmaceuticals (Head of Cancer Biology in the U.S.), and senior management positions at several Biotechnology companies, where he also managed drug discovery programs in inflammation, diabetes, and infectious disease. Michael received a Bachelor’s degree in biology from the University of California at San Diego, a Ph.D. in cell and developmental biology from Harvard Medical School (National Science Foundation Pre-doctoral Fellow) and carried out post-doctoral research at Cornell University.

How old is Michael James Newman?

Dr. Newman is currently 68 years old. There are 4 older executives and no younger executives at Indaptus Therapeutics. Learn More on Michael James Newman's age.

How do I contact Michael James Newman?

The corporate mailing address for Dr. Newman and other Indaptus Therapeutics executives is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. Indaptus Therapeutics can also be reached via phone at (646) 427-2727 and via email at [email protected]. Learn More on Michael James Newman's contact information.

Has Michael James Newman been buying or selling shares of Indaptus Therapeutics?

Michael James Newman has not been actively trading shares of Indaptus Therapeutics over the course of the past ninety days. Most recently, Michael James Newman sold 5,870 shares of the business's stock in a transaction on Monday, January 31st. The shares were sold at an average price of $5.00, for a transaction totalling $29,350.00. Learn More on Michael James Newman's trading history.

Who are Indaptus Therapeutics' active insiders?

Indaptus Therapeutics' insider roster includes Jeffrey Meckler (CEO), and Michael Newman (Director). Learn More on Indaptus Therapeutics' active insiders.

Michael James Newman Insider Trading History at Indaptus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2022Sell5,870$5.00$29,350.00View SEC Filing Icon  
See Full Table

Michael James Newman Buying and Selling Activity at Indaptus Therapeutics

This chart shows Michael James Newman's buying and selling at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indaptus Therapeutics Company Overview

Indaptus Therapeutics logo
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $0.94
Low: $0.89
High: $0.95

50 Day Range

MA: $1.16
Low: $0.89
High: $1.91

2 Week Range

Now: $0.94
Low: $0.84
High: $3.10

Volume

23,784 shs

Average Volume

59,681 shs

Market Capitalization

$9.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46